R-CHOP is a combination chemotherapy regimen used to treat several types of non-Hodgkin lymphoma. The name is an acronym for its five components: rituximab, cyclophosphamide, doxorubicin (also called hydroxydaunorubicin), vincristine (brand name Oncovin), and prednisone. It has been the standard first-line treatment for diffuse large B-cell lymphoma (DLBCL), the most common form of non-Hodgkin lymphoma, for over two decades.
What Each Drug Does
The five drugs in R-CHOP attack cancer cells through different pathways, which is why they work well together. Rituximab is a targeted therapy, not a traditional chemotherapy drug. It’s an antibody that locks onto a protein called CD20 found on the surface of B cells, the immune cells that become cancerous in these lymphomas. Once attached, it triggers the immune system to destroy those cells through several mechanisms, including signaling immune cells to attack and activating proteins that punch holes in the cancer cell membrane.
Cyclophosphamide and doxorubicin are the heavy hitters of the regimen. Cyclophosphamide damages the DNA inside cancer cells so they can’t divide. Doxorubicin works similarly but also interferes with enzymes the cell needs to copy its DNA. Vincristine takes a different approach, disrupting the internal scaffolding cells use to pull apart during division, which stops them from multiplying. Prednisone is a steroid that reduces inflammation, helps kill lymphoma cells directly, and lessens some of the side effects caused by the other four drugs.
Which Cancers R-CHOP Treats
R-CHOP is primarily used for DLBCL, but oncologists also prescribe it for advanced follicular lymphoma, mantle cell lymphoma, and Waldenström macroglobulinemia. The regimen works specifically against B-cell lymphomas because rituximab targets the CD20 protein on B cells. It would not be appropriate for T-cell lymphomas or cancers that don’t express that protein.
How Treatment Is Administered
A standard course of R-CHOP consists of six cycles, each lasting 21 days. On the first day of each cycle, you receive rituximab, cyclophosphamide, doxorubicin, and vincristine through an IV at an infusion center. The visit can take several hours, particularly during the first cycle when rituximab is infused slowly to watch for reactions. Prednisone is the one oral component, taken as pills for five days at the start of each cycle.
Before the rituximab infusion, you’ll typically receive premedications to reduce the chance of a reaction. These usually include a steroid, antihistamines, and acetaminophen. Infusion reactions are most common during the first dose, with symptoms like flushing, itching, and feeling hot. They tend to start within the first hour of infusion. With a comprehensive premedication approach, the reaction rate drops to around 24%, compared to over 50% with minimal premedication.
Because R-CHOP significantly lowers white blood cell counts, many patients receive an injection of a growth factor drug the day after each infusion. This stimulates the bone marrow to produce more white blood cells and reduces the risk of dangerous infections. Guidelines recommend this support when the risk of fever from low white blood cell counts is 20% or higher, and CHOP-based regimens meet that threshold. Patients over 65, or those with other health conditions, are especially likely to need it.
How Effective R-CHOP Is
For DLBCL patients who receive full-dose R-CHOP, the five-year overall survival rate is roughly 62%, and about 58% of patients remain disease-free at five years. These numbers come from a large study of patients over 60, so younger patients with fewer health issues generally do better. Many people with DLBCL are cured by R-CHOP, meaning the cancer never returns after treatment.
A newer regimen called Pola-R-CHP has recently emerged as an alternative. It swaps vincristine for a different targeted drug (polatuzumab vedotin) and showed a sustained benefit in a large clinical trial called POLARIX. At five years, 65% of patients on Pola-R-CHP were progression-free compared to 59% on standard R-CHOP. Based on these results, Pola-R-CHP is now considered another standard option for frontline DLBCL treatment, particularly for patients with intermediate or high-risk disease.
Common Side Effects
Nearly all patients on R-CHOP experience some drop in white blood cell counts. In one study tracking 75 patients, 96% developed low white blood cell levels, 35% had low platelet counts, and 27% became anemic. These blood count changes are temporary but require careful monitoring because they increase the risk of infections and bleeding, particularly in the days following each infusion.
Beyond blood counts, the most frequently reported side effects are digestive. Constipation affected 56% of patients, loss of appetite 52%, and nausea or vomiting about 47%. Peripheral neuropathy, a tingling or numbness in the hands and feet caused primarily by vincristine, occurred in 31% of patients. About a third of patients reported insomnia, and 15% developed mouth sores. Hair loss is also very common with doxorubicin, though hair typically grows back after treatment ends.
Heart Health and Long-Term Monitoring
Doxorubicin, one of the most effective drugs in the regimen, carries a well-known risk of heart damage. The risk rises sharply when the total lifetime dose exceeds 450 to 550 mg per square meter of body surface area. A standard six-cycle course of R-CHOP typically stays well below this ceiling, but the cumulative dose matters if you ever need doxorubicin again for a future cancer.
Before starting treatment, your oncologist will check your heart function with an echocardiogram or similar imaging to establish a baseline measurement of how well your heart pumps. This measurement, called the ejection fraction, will be rechecked periodically during and after treatment. Newer imaging techniques can detect subtle changes in heart muscle function before the ejection fraction drops, allowing earlier intervention if problems develop. Patients who had pre-existing heart conditions or who received higher cumulative doses may need ongoing cardiac monitoring for years after completing R-CHOP.
What to Expect During Treatment
A full course of R-CHOP takes about four and a half months (six 21-day cycles). Most people feel worst in the week following each infusion, when blood counts are at their lowest and nausea is most likely. Energy levels often improve in the second and third weeks of each cycle before the next round begins. Many people continue working or maintaining modified routines during treatment, though fatigue tends to build with successive cycles.
Between cycles, you’ll have blood draws to check that your counts have recovered enough to proceed on schedule. If counts are too low, your oncologist may delay the next cycle by a few days. Maintaining the full dose and timing of each cycle is important for the best outcomes, which is why growth factor support and other preventive measures are used aggressively to keep treatment on track.